The Evidence Blueprint

Behavioral Health • Real-World Data • Research Grade

Leverage our platform to accelerate drug development and commercialization, and innovation in care delivery with Real-World Insights.

The Challenge

Clinical practice is not always conducive to capture objective measures in behavioral health.

Lack of quantitative data hinders innovation, development and commercialization of new treatments.
our solution
Research-grade behavioral health Real-World Data with validated outcome measures and advanced analytics tools.
Largest longitudinal behavioral health Real-World Dataset
  • Sourced from MindLinc EHR - acquired from Duke University School of Medicine in 2016
  • 50+ million rows of data
  • Across 25+ sites
  • Data from an additional 1 million+ patients to be added in 2021
Enhanced data with custom Natural Language Processing
  • De-identified, aggregated and normalized to a common data model
  • Enhanced with neuropsychiatry-specific natural language processing to transform clinician notes into 300+ validated labels
  • 500+ validated labels expected by end of 2020
User-friendly analytics tools
  • Rapid onboarding with dedicated customer support and support tools
  • Augmented by our experience in advanced analytics
Use Cases
Drive clinical and commercial success
Enhance Clinical Trial Design
By understanding real world patients
Value
Assess disease burden, patient phenotypes, treatment patterns, comorbidities and unmet needs.
Use Cases
  • Understand acute phases of Major Depressive Disorder to inform clinical development of a treatment-resistant depression drug candidate.
  • Identify unmet needs in substance use disorder patient subgroups that have received optimal treatment.
Generate evidence
To differentiate products in the real world
Value
Assess real world comparative outcomes among drugs and understand clinical context driving prescription behaviors.
Use Cases
  • Sub-stratification of schizophrenia patients for better characterization and treatment planning.
  • Quantify comparative function and patient engagement signals for anti-psychotics.
Testimonials
CEO, Optum Ventures
jane doe
Amet minim mollit non deserunt ullamco est sit aliqua dolor do amet sint. Velit officia consequat duis enim velit mollit. Exercitation veniam consequat sunt nostrud amet.
CEO, Optum Ventures
jane doe
Amet minim mollit non deserunt ullamco est sit aliqua dolor do amet sint. Velit officia consequat duis enim velit mollit. Exercitation veniam consequat sunt nostrud amet.
CEO, Optum Ventures
jane doe
Amet minim mollit non deserunt ullamco est sit aliqua dolor do amet sint. Velit officia consequat duis enim velit mollit. Exercitation veniam consequat sunt nostrud amet.

Request a Demo

Or have a question?
Email us at
- or -
Message sent successfully!
Oops! Something went wrong while submitting the form.
Looking for more information on NeuroBlu™?
Download our product flyer here.
DOWNLOAD